Advancing Cardiorenal Interaction: From Pathophysiological Paradigms to Novel Therapeutic Strategies
Future clinical trials should adopt dual cardiorenal endpoints to better evaluate treatment effects. Combination therapies require rigorous investigation to establish optimal efficacy and safety profiles. These advances hold promise for optimizing multidisciplinary care, reducing disease burden, improving patient outcomes, and enhancing global health.
Authors
- Xiaoxuan Ning (ORCID: https://orcid.org/0000-0002-5367-707X)
- Lijuan Zhao
- Liuyifei Huang
- Peng He
- Ruijing Zhang (ORCID: https://orcid.org/0000-0002-0044-1573)
- Shanshan Sun (ORCID: https://orcid.org/0000-0002-6286-3114)
- Xiang Gao (ORCID: https://orcid.org/0000-0003-2617-6509)
- Lei Wei (ORCID: https://orcid.org/0000-0002-4739-9392)
Institutions
- Xijing Hospital (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Kidney Diseases
- Published
- 2025-09-18
- DOI
- https://doi.org/10.1159/000548367
- Citations
- 1
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- National Natural Science Foundation of China